career programming sessions final
TRANSCRIPT
![Page 1: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/1.jpg)
Prepare Your Team to Collaborate in the Industry’s
New Business Models
Tuesday, November 15
Bart HENSCareer Zone Classroom
![Page 2: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/2.jpg)
Please don’t forget to complete the satisfaction
survey!• AAPS 2016 Annual Meeting App
![Page 3: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/3.jpg)
Pharmaceutical Industry
MANAGEMENT SCIENCE
![Page 4: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/4.jpg)
Collaborative Negotations
![Page 5: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/5.jpg)
Closed versus Open business models
Transparency, globilization, data sharing,...
INNOVATIONproduct success rate of more than 50% and an increase of research & development (R&D) efficiency with more than 60%
Kaitin KI, DiMasi JA. 2011. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89:183–188.
![Page 6: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/6.jpg)
Learning Objectives• Network with the right people that will contribute
positively to your project: Who are the right people to select to make this project a success?
• Create a logical, manageable workplan to make sure you will have a successful project from the start.
• Identify the key components of a truly collaborative environment that you should look for: What is the expertise of each company and how can they contribute to the project?
• Know and avoid the pitfalls of poorly structured collaborative environments.
Whenever keeping these objectives in mind, the chances to obtain project approval, funded by external sources, will increase!
![Page 7: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/7.jpg)
Case Study with OrBiTo and PEARRL project
How to go for an open business model?
“To predict the in vivo performance of oral drug products across all stages of drug development”
“Safe and effective new medicines faster”
OrBiTo PEARRL
€ 24 million € 3,9 million
5 year period 3 year period
13 pharmaceutical companies 6 pharmaceutical companies+4 regulatory affair partners
14 academic partners 6 academic partners
![Page 8: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/8.jpg)
Project Main Objective: OrBiTo"Oral Bioavailability Tools"• Optimizing in vitro and in silico biopharmaceutical
tools to empower their predictions towards the in vivo outcome of the drug.
![Page 9: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/9.jpg)
Project Main Objective: PEARRL
PEARRL will drive innovation, economic growth and create job opportunities for highly qualified researchers with its emphasis on
excellent science, industrial leadership and tackling societal challenges.
![Page 10: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/10.jpg)
1. Network with the right people:
Multidisciplinary Approach
Project
Industrial partners
Academic
partnersSME’s
EDAN conference: European Drug Absorption Network initiated negotations among different partners to start OrBiTo:• Combining different expertises of each company• + combining different expertises of each academic institution
![Page 11: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/11.jpg)
IMI OrBiTo project – innovative tools for oral biopharmaceutics
• OrBiTo consortium comprises 13 EFPIA companies with 14 academic centres and SME companies• Managing entity: Uppsala Univ (Hans Lennernäs/Krister Halldin).• Scientific coordinators:Astrazeneca (Bertil Abrahamsson) & Pfizer (Mark McAllister)
![Page 12: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/12.jpg)
2. Create a workplan
![Page 13: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/13.jpg)
3. Identify the key components of a truly collaborative environment
In-house neutral compounds In-house basic compounds
Stomach Duodenum
pH p
robe
pH p
robe
Different expertises lead to different models to test and to cross-validate during the project
![Page 14: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/14.jpg)
3. Identify the key components of a truly collaborative environment
![Page 15: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/15.jpg)
4. Avoid pitfalls
• What about shared data after the project?• Policies/agreements?
• Dissemination of data before it can be shared with the entire scientific world
Make sure to define rights and duties prior to the start of the project!
![Page 16: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/16.jpg)
4. Avoid pitfalls• Ethical Concerns:
• What about medical issues that will occur during the project?
• Example: healthy volunteer of your clinical study seemed to have HIV-1 after analysis of his blood. Who will and is responsible to communicate this issue?
![Page 17: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/17.jpg)
5. Schedule meetings to stay up-to-date• Monthly conference calls among work packages• Annual F2F meetings to have a general overview of
the project and to discuss future perspectives, challenges and opportunities
Annual OrBiTo Meeting 2015 Paris, France
![Page 18: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/18.jpg)
6. Training of young scientists“The youth of today are the leaders of tomorrow”
• Local training activities versus networking • Webinars, poster sessions, work shops, internships,...• The power of Social Media
![Page 19: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/19.jpg)
7. Success will lead to more success
2.0 2.0
![Page 20: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/20.jpg)
Design your own project
Developing an interactive collaboration among industry and academic partners to find a cure for
HIV-1.
![Page 21: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/21.jpg)
4) Discussion data and next steps?
3) Overview of the project?
5) Training of young scientist?
6) Pitfalls?
7) How will the project stimulate next collaborations?
2) How to recruit?
1) Kind of people?
Road to Success/Innovation
![Page 22: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/22.jpg)
Questions
Bart Hens – [email protected] Delivery & DispositionHerestraat 49, Box 9213000 Leuven
: bart hens
: @HensBart
: Bart Hens
: Bart Hens
![Page 23: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/23.jpg)
Please don’t forget to complete the satisfaction
survey!• AAPS 2016 Annual Meeting App
![Page 24: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/24.jpg)
Acknowledgments
the Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115369, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program and EFPIA companies’ in kind contribution.
https://www.orbitoproject.eu
This project has received funding from the European Union’s Horizon 2020 Research and Innovation program under agreement number no 674909
https://www.pearrl.eu
Young Orbito is a community of young scientists, represented by PhD students & postdocs, who intensively contribute to the IMI and EFPIA funded project Orbito.
https://www.youtube.com/watch?v=xt3zESkbm7g
![Page 25: Career programming sessions final](https://reader034.vdocuments.net/reader034/viewer/2022042723/5883d3851a28abb7308b6eb9/html5/thumbnails/25.jpg)
References• S. Wu-Pong, J. Gobburu, S. O’Barr, K. Shah, J. Huber, and D. Weiner, “The
Future of the Pharmaceutical Sciences and Graduate Education: Recommendations from the AACP Graduate Education Special Interest Group,” Am. J. Pharm. Educ., vol. 77, no. 4, May 2013.
• J. Hunter and S. Stephens, “Is open innovation the way forward for big pharma?,” Nat. Rev. Drug Discov., vol. 9, no. 2, pp. 87–88, Feb. 2010.
• Kaitin KI, DiMasi JA. 2011. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89:183–188.